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CD127low/ and FoxP3þ Expression Levels
Characterize Different Regulatory T-Cell Populations
in Human Peripheral Blood
Sandra Klein1, Cosima C. Kretz1, Peter H. Krammer1 and Annegret Kuhn1,2
It has recently been suggested that a lack of CD127 expression can be used to identify human CD4þ regulatory
T cells (Tregs), especially when combined with CD25. Therefore, we analyzed CD4þCD25þCD127low/ cells and
compared their frequency and expression pattern with those of FoxP3þ Tregs using multiparameter flow
cytometry analysis. We obtained human peripheral blood cells from 20 normal healthy donors and determined
the number of CD25þCD127low/ cells as a percentage of CD4þ T cells in the same panel used for
CD4þCD25þFoxP3þ cells. In contrast to CD4þCD25þFoxP3þ cells, gating of a clear CD4þCD25þCD127low/
population was difficult. Moreover, we demonstrated that there was a high percentage (34.0±15.1%) of
CD127low/ cells that did not express FoxP3 and, conversely, that there was a high percentage (30.3±7.4%)
of CD127þ cells that expressed FoxP3, suggesting that these markers did not represent the same population
of Tregs. These data were also confirmed in blood samples from patients with systemic scleroderma. Thus,
isolation of pure Treg populations for in vitro functional studies is a challenge, explaining the varying results by
different groups in clinical studies. The data from this study have important implications for carrying out a
quantitative analysis of Tregs in human samples.
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INTRODUCTION
The identification of CD4þCD25þ regulatory T cells (Tregs),
an important cellular component involved in the establish-
ment of self-tolerance, has opened a major area of investiga-
tion in immunology (Shevach, 2002; Sakaguchi, 2004). The
capacity of Tregs to suppress pathological immune responses
in autoimmune diseases has been demonstrated in numerous
experimental models (Suri-Payer and Fritzsching, 2006).
Functional analysis of murine Tregs showed that they fail to
proliferate or secrete cytokines in response to polyclonal or
antigen-specific stimulation, but that they inhibit the activation
of conventional T cells (Thornton and Shevach, 1998). More
recently, Tregs have been identified and characterized in
humans (Jonuleit et al., 2000; Wing et al., 2002), and several
studies have reported an aberrant number and/or function of
Tregs in various human autoimmune diseases (Dejaco et al.,
2006). However, it has been impossible to compare results
from the literature, in terms of both numbers and functionality
of Tregs, particularly in inflammatory conditions. This may be
due at least in part to the difficulty in accurately distinguishing
Tregs from activated CD25þ conventional T cells, particularly
in human samples, in which up to 30% of CD4þ T cells can
express CD25 (Baecher-Allan et al., 2001).
The discovery of the transcription factor FoxP3 as a major
marker of Treg development and function has been a
significant advance in the study of mouse and human Tregs
(Fontenot et al., 2003; Gambineri et al., 2003; Hori et al.,
2003; Khattri et al., 2003). Several investigations in mice
showed that FoxP3-deficient animals lack Tregs, whereas an
overexpression of FoxP3 leads to profound immune suppres-
sion (Ziegler, 2006). Although recent studies have questioned
whether all Tregs are FoxP3þ or all FoxP3þ T cells are
regulatory, the FoxP3 protein remains the best and most
specific marker of Tregs to date. Meanwhile, a good panel of
mAbs to detect FoxP3 by flow cytometric and immunohis-
tochemical analyses is commercially available. Given that
FoxP3 is an intracellular molecule, however, detection of
FoxP3 requires fixation and permeabilization of cells; hence
this technique cannot be used to isolate viable Treg
populations for functional studies and for ex vivo expansion
as a prelude to therapeutic administration. Therefore, it is of
interest to identify a cell-surface marker that correlates with
FoxP3 and might even represent a single marker for Treg
purification independent of CD25 expression.
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Recent reports by different groups have specifically
addressed this issue by demonstrating that surface expression
of CD127, the a-chain of the IL-7 receptor, in combination
with CD25 can distinguish between human regulatory and
conventional CD4þ T cells in adult and cord blood,
lymph nodes, and thymus (Liu et al., 2006; Seddiki et al.,
2006a; Hartigan-O’Connor et al., 2007). In these studies,
CD127low/–FoxP3þ T cells accounted for a significant
percentage of CD4þ T cells in peripheral blood, and, in
addition, the isolated CD4þCD127low/– T-cell subset was
anergic and suppressed alloantigen responses in vitro.
Together, these data suggested a dichotomy between memory
T cells (namely, IL-2RlowIL-7Rhigh cells) and regulatory
FoxP3þ T cells, which, in most instances, upregulate IL-2R
while remaining IL-7Rlow/– (Liu et al., 2006; Ziegler, 2006). It
was concluded that the low cell-surface expression of CD127
allows for an accurate estimation of Treg numbers and the
isolation of pure populations for in vitro studies, providing a
flexible alternative to the transcription factor FoxP3 for
identifying and isolating human Tregs for functional analysis
and potentially in vivo therapeutic strategies.
In this study, we analyzed CD4þCD25þCD127low/– cells
and compared their frequency and expression pattern with
those of CD4þCD25þFoxP3þ cells from normal healthy
donors (NHDs) by flow cytometry analysis. The low surface
expression of CD127 in combination with CD25, however,
did not reflect the number of FoxP3þ Tregs in human
peripheral blood CD4þ cells, suggesting that CD127 cannot
be used selectively to enrich human Tregs and isolate pure
populations for functional in vitro studies. In addition, we
demonstrate that studies with isolated CD127low/– Tregs
should be interpreted with caution in human autoimmune
diseases.
RESULTS
Frequency of CD4þCD25þFoxP3þ Tregs in peripheral blood
of NHDs
To define the frequency of circulating CD4þCD25þFoxP3
cells, peripheral blood samples from 20 NHDs were purified
on Ficoll gradients and stained with anti-CD4 and anti-CD25
mAbs. This was followed by cell-membrane permeabilization
and intracellular staining with anti-FoxP3 antibody. Periph-
eral blood mononuclear cells (PBMCs) were gated for CD4þ
T cells (Figure 1a), and the percentage of CD25þFoxP3þ
cells among CD4þ T cells (Figure 1b) was determined. To
define CD4þCD25þFoxp3þ Tregs, we used a contour plot.
Thus, a clear population of CD4þCD25þFoxP3þ cells could
be gated consistently over time and was comparable in each
experiment and in different individuals. The median of
CD25þFoxP3þ Tregs among CD4þ T cells in NHDs was
similar to that previously reported (7.7%; range 4.4–13.0%).
No significant staining was observed using an isotype control
IgG (data not shown).
Determination of CD4þCD25þCD127low/ cells in peripheral
blood of NHDs
Recently, it was reported that human CD4þ Tregs can be
distinguished by a low level of surface CD127 (Liu et al.,
2006; Seddiki et al., 2006a; Hartigan-O’Connor et al., 2007),
suggesting that the CD4þCD25þCD127low/ population
comprises a clearly distinct group of cells. In addition, it
has been proposed that CD127 can be used to selectively
enrich human Tregs for functional in vitro studies and
potentially in vivo therapy, especially when combined
with CD25 as a marker. Therefore, we determined the
number of CD25þCD127low/ cells as a percentage of CD4þ
T cells in the same panel used for the determination of
CD4þCD25þFoxP3þ cells. In contrast to the gating of
FoxP3þ cells using flow cytometry analysis, it was not
obvious where to define the boundary between CD127low/
and CD127þ expression in either the dot plot (Figure 2a) or
the contour plot (Figure 2b). Thus, a clear population of
CD4þCD25þCD127low/ cells may not be gated consis-
tently over time in clinical studies.
To evaluate whether the permeabilization procedure
influenced the quantification of CD25þCD127low/ cells,
PBMCs were gated for CD4þ T cells, and the percentage of
CD25þCD127low/ cells among the CD4þ T cells was
determined in a separate panel without permeabilization and
intracellular staining for FoxP3. As shown in Figure 2c, there
was no significant difference (P¼0.4328) between the
number of CD25þCD127low/ cells among the CD4þ T
cells with and without permeabilization in the same blood
samples of nine NHDs.
Expression of FoxP3 within the CD25þCD127low/ population
and on different CD4þ T-cell subsets
To measure the expression of FoxP3 and CD127 within
different CD4þ subsets, PBMCs from the peripheral blood of
NHDs were stained with mAbs against CD4, CD25, CD127,
and FoxP3. By using multiparameter flow cytometry, the
strength of the correlation between the percentages of
CD25þCD127low/ and CD25þFoxP3þ cells among all
CD4þ cells was determined (Figure 3). The overwhelming
majority of CD4þCD25þCD127low/ cells were FoxP3þ
(95.5% in this individual); however, there was also a high
percentage (52.3% in this individual) of FoxP3þ T cells in the
CD4þCD127þ subset among those that expressed CD25.
Thus, a broad gating strategy of CD4þCD25þCD127low/
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Figure 1. Gating strategy for CD4þCD25þFoxP3þ cells. To define the
number of circulating CD4þCD25þFoxP3þ cells, human peripheral blood
mononuclear cells (PBMCs) from normal healthy donors (NHDs) were
purified from peripheral blood samples and stained for CD4, CD25,
and FoxP3. CD4þ T cells were gated out of lymphocytes (a), and the
percentage of CD4þCD25þFoxP3þ cells among the CD4þ T cells (b)
was determined.
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resulted in a highly purified FoxP3þ T-cell population;
however, FoxP3þ cells were also detected in the
CD4þCD25þCD127þ population.
Because a high expression of CD25 has been proposed to
be an indicator of suppressive capacity, we applied a reverse
gating strategy. First, we differentiated CD25þ þ , CD25þ ,
and CD25 cells of CD4þ T cells in order to determine the
number of CD127low/, FoxP3þ , and CD127low/FoxP3þ
cells (Supplementary Figure S1a–d). This analysis showed that
89.6±4.7% of T cells that highly express CD25 are negative
for CD127; 88.1±5.9% of these CD25þ þ cells express
FoxP3 and 84.9±8.1% are CD127low/FoxP3þ . The percen-
tages of CD127low/, FoxP3þ , and CD127low/FoxP3þ cells
are lower in the CD25þ (35.2±6.0, 25.7±8.7, and
23.4±9.2%, respectively) and the CD25 sub-populations
(26.5±8.9, 0.9±0.4, and 0.7±0.4%, respectively). Never-
theless, the values of CD127low/ cells are still high in CD25
cells. Thus, FoxP3 shows a better correlation with the Treg
phenotype.
Lack of correlation between the expression of FoxP3 and
CD127/low in CD4þCD25þ T cells
To study the correlation between the expression of FoxP3 and
CD127/low in CD4þCD25þ T cells, statistical analysis was
performed after staining PBMCs for the expression of CD4,
CD25, CD127, and FoxP3, using multiparameter flow
cytometry. PBMCs were gated for CD4þ cells and analyzed
for CD25 and Fox P3 or CD127. As shown in Figure 4,
30.3±7.4% of CD4þCD25þFoxP3þ cells (P3, cells shown
in yellow) were not detected by gating the CD25þCD127low/
cells out of the CD4þ cells (Figure 4b). Conversely,
34.0±15.1% of the CD4þCD25þCD127low/ cells (P6: cells
shown in green) were CD4þCD25þFoxP3. In summary,
only 69.7±7.4% of the CD4þCD25þFoxP3þ cells (gated as
in Figure 4a, P3: cells marked in grey) fell within the
CD4þCD25þCD127low/ population (Figure 4b). Conversely,
66.0±15.5% of the CD4þCD25þCD127low/ cells (gated as
in Figure 4b, P5: gray) were also detected within the
CD4þCD25þFoxP3þ population (Figure 4a). Although the
expression of CD127 in combination with CD25 was better
than the single expression of CD25 for the determination of
CD4þFoxP3þ T cells, PBMCs that stained for CD4, CD25,
and CD127 were not identical to the cells expressing FoxP3.
Comparison of CD4þCD25þCD127low/ and
CD4þCD25þFoxP3þ cell numbers in patients with systemic
sclerosis
Previous studies suggested that Treg numbers might be
impaired in human autoimmune diseases such as systemic
lupus erythematosus (Kuhn et al., 2009). To investigate Treg
populations in patients with another connective tissue
disease—namely, systemic sclerosis (SSc), or scleroderma—
peripheral blood samples were stained with CD4, CD25,
CD127, and FoxP3 as described for NHDs. Representative
examples (contour plot) of CD4þCD25þCD127low/ and
CD4þCD25þFoxP3þ cells in a patient with SSc are shown
in Figure 5a. Interestingly, in patients with SSc, 35.5±6.1%
of CD4þCD25þFoxP3þ cells were not detected among the
CD4þCD25þCD127low cells. Conversely, 40.7±13.6% of
CD4þCD25þCD127low cells were CD4þCD25þFoxP3
(Figure 5b). In summary, only 64.5±6.4% of
CD4þCD25þ /þ þFoxP3þ cells were detected within the
CD4þCD25þ /þ þCD127low population, and 59.3±13.6%
of CD4þCD25þCD127low/ cells were detected within the
CD4þCD25þFoxP3þ population.
Statistical analysis also revealed that the number of
CD4þCD25þCD127low/ cells (7.4%, range 5.7–17.7%) in
12 patients with SSc was slightly lower than the number of
CD4þCD25þFoxP3þ cells (8.2%, range 4.5–14.0%); how-
ever, this was not statistically significant (P¼0.3793)
(Figure 6). In flow cytometric analysis of 20 NHDs, the
CD4þCD25þCD127low/ subset in NHDs showed a median
of 7.9% (range 5.5–12.2%) vs. 7.7% (range 4.4–13.0%) for
CD4þCD25þFoxP3þ cells, which was not a statistically
significant difference (P¼0.3693). No significant difference
was detected when comparing the frequency of
CD25þFoxP3þ cells and CD25þCD127low/ cells among
all CD4þ T cells between NHDs and SSc patients
(P¼0.9689 and P¼ 0.8002, respectively). This was also the
case for the gating strategy of CD127low/, FoxP3þ , and
CD127low/FoxP3þ cells of CD25þ þ , CD25þ , and CD25
subpopulations (Supplementary Figure S1e, f).
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Figure 2. Frequency of CD4þCD25þCD127low/ cells. To define the
number of circulating CD4þCD25þCD127low/ cells, human peripheral
blood mononuclear cells (PBMCs) from normal healthy donors (NHDs) were
purified from peripheral blood samples and stained for cell surface expression
of CD4, CD25, and CD127. The PBMCs were gated for CD4þ T cells (data
not shown; see Figure 1a), and the percentage of CD4þCD25þCD127low/
cells among the CD4þ T cells was determined using a dot plot (a) or contour
blot (b). It is not obvious, however, where to set the boundary between
CD127low/ and CD127þ expression in either analysis. Therefore, a clear
population of CD4þCD25þCD127low/ cells might not be gated consistently
over time. To determine whether the permeabilization procedure had any
influence on the quantification of CD4þCD25þCD127low/ cells, cells from
the same NHDs were stained with and without permeabilization (c), but no
significant difference was observed (P¼ 0.4328).
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DISCUSSION
Despite the emergence of Tregs as an essential cell
population in maintaining immune tolerance and advances
in understanding the mechanisms underlying Treg lineage
commitment and function, purification of Tregs has still relied
largely on their CD4þCD25þ phenotype. It was recently
reported that human CD4þ Tregs can be distinguished by a
low level of surface CD127, suggesting that the
CD4þCD25þCD127low/ population comprises a clearly
distinct group of cells (Liu et al., 2006; Seddiki et al., 2006a;
Hartigan-O’Connor et al., 2007). In this study, we purified
PBMCs from peripheral blood samples of NHDs and
determined the number of CD25þCD127low/ cells as a
percentage of CD4þ T cells using flow cytometric analysis. It
was difficult to define the boundary between CD127low/
and CD127þ expression in the dot and contour
plots, however, suggesting that a clear population of
CD4þCD25þCD127low/ cells might not be gated consis-
tently over time in clinical studies. In contrast, gating of
CD25þFoxP3þ cells was obvious when determined as a
percentage of CD4þ T cells in the same panel used for the
analysis of CD4þCD25þCD127low/ cells.
The transcription factor FoxP3 has been shown to
represent a master control gene for the development and
function of naturally occurring Tregs. Therefore, FoxP3 is
currently the best available marker to identify Tregs, given
that not only is it found in the CD4þCD25high population but
also its expression corresponds to the acquisition of a Treg
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Figure 3. Expression of FoxP3 and CD127 in different CD4þ subsets. To define the expression of Foxp3 and CD127 in different CD4þ subsets, human
peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood and stained for CD4, CD25, FoxP3, and CD127. Expression of FoxP3 in
CD4þCD127low/ and CD4þCD127þ T-cell subsets was determined. Boxes represent arbitrary designations of CD127þ vs. CD127low/ cells. Each number in
the histograms indicates the percentage of gated cells expressing FoxP3. As shown in P14, a high number of CD4þCD127þCD25þþ cells obviously expressed
FoxP3, and a low number of CD4þCD127þCD25þ / cells expressed FoxP3 (P13).
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phenotype (Fontenot et al., 2003; Hori et al., 2003; Yagi et al.,
2004). Studies using FoxP3 as a marker, however, suggest that
there may be a larger population of Tregs in human peripheral
blood than previously appreciated. In this regard, flow
cytometric and immunohistochemical analyses have shown
that FoxP3 is expressed in significantly more T cells
than previously identified, using other available cell-surface
markers, including CD25. FoxP3 protein is found in
CD25low/CD4þ T cells and under certain conditions in
some CD8þ T cells (Bisikirska et al., 2005; Ziegler, 2006).
Thus, it is likely that many of the natural and adaptive Tregs
are missed in current studies, calling into question the
conclusions related to deficiencies or defects in certain
autoimmune conditions. Moreover, because FoxP3 is an
intracellular molecule that requires cell fixation and permea-
bilization for detection, it cannot be used to separate
human Tregs for functional studies or for in vivo expansion
for cellular therapy, thereby limiting its use in human
diseases. To evaluate whether the permeabilization procedure
influenced the quantification of CD127low/ cells in our
study, PBMCs were gated for CD4þ T cells and the percentage
of CD25þCD127low/ cells among the CD4þ T cells was
determined in a separate panel, without permeabilization
or intracellular staining for FoxP3. No significant difference
was found between the number of CD25þCD127low/ cells
among the CD4þ T cells with and without permeabilization in
the same NHDs.
Our data from normal peripheral blood further demon-
strated that, although the vast majority of
CD4þCD25þCD127low/ cells were FoxP3þ , there was
also a large percentage of FoxP3þ cells in the
CD4þCD127þ subset among those that expressed CD25.
Further statistical analysis showed that only 69.7% of
CD4þCD25þFoxP3þ cells were found within the
CD4þCD25þCD127low/ cell population by multiparameter
flow cytometry. Conversely, 66.0% of CD4þ
CD25þCD127low/ cells were detected within the CD4þ
CD25þFoxP3þ population. Although expression of CD127
in addition to CD25 seemed to be better than the single
expression of CD25 for the determination of Tregs, PBMCs
stained for CD4, CD25, and CD127 were not identical to
cells expressing FoxP3. Furthermore, we demonstrated that
the number of CD127low/ cells among the CD4þCD25þþ
cells is comparable to that of FoxP3þ cells of the same
population. Nevertheless, comparing the numbers of
CD127low/ cells and FoxP3þ cells among the CD4þCD25
subpopulation showed different results; therefore, the use of
the additional marker CD127 does not improve the quality of
purified Tregs. Our results are in line with the data of Shen
et al. (2009) showing an increased number of CD127low/
cells and FoxP3þ cells with CD25 as an additional marker.
However, these authors further found that, although FoxP3
was predominantly expressed by CD4þCD25þCD127low/
cells, only 12.2% of CD4þCD25CD127low/ cells were
analyzed as FoxP3 positive. These results are in contrast to
our data of the subpopulation differentiation based on CD127
and the finding of 48.1% CD4þCD25CD127low/ cells by
Liu et al. (2006), which corresponds to our data.
It has been speculated that Tregs may not require IL-7, in
contrast to many non-Treg subsets that are IL-2 independent
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Figure 4. Correlation between CD4þCD25þFoxP3þ cells and CD4þCD25þCD127low/ cells in normal healthy donors (NHDs). Peripheral blood
mononuclear cells (PBMCs) were isolated from peripheral blood of NHDs and stained for CD4, CD25, aCD127, and FoxP3. PBMCs were gated for CD4þ T cells
(data not shown; see Figure 1a), and CD4þCD25þFoxP3þ cells and CD4þCD25þCD127low/ cells among the CD4þ T cells were determined. Subsequently,
the correlation between these two populations was examined (a, b). Of the CD4þCD25þFoxP3þ cells (a, P3), 30.3% (a, P3, cells shown in yellow) did not fall
in the CD4þCD25þCD127low/ population (b, P6) but instead fell outside of this population (b, cells shown in yellow). Conversely, 34.0% (b, P6, cells
shown in green) of the CD4þCD25þCD127low/ cells (b, P6) could not be detected in the CD4þCD25þFoxP3þ population but instead fell outside of this
population (a, P5, cells show in green).
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but require IL-7 (von Freeden-Jeffry et al., 1995). Consistent
with this hypothesis, it has recently been demonstrated that
human Tregs consistently express lower levels of CD127 than
the majority of other CD4þ T cells. Two groups who
investigated the relationship among CD25, FoxP3, and
CD127 protein expression in CD4þ T cells from adult
human peripheral blood using flow cytometry confirmed that,
within the CD4þCD25þ population, there was a significant
correlation between FoxP3 and the CD127low/ phenotype
(Liu et al., 2006; Seddiki et al., 2006a). In mice, CD127 has
been suggested to be a better marker than CD25, with most
CD4þFoxP3þ T cells having a CD127low/ phenotype (Liu
et al., 2006). Liu et al. (2006) further demonstrated that FoxP3
binds to the CD127 promoter region, leading them to propose
that this might reflect a direct repression of CD127 by FoxP3.
Seddiki et al. (2006b), investigating a wider range of human
tissues, determined that FoxP3þ cells in both lymph node
and cord blood were CD127low/ and showed that the size of
this population was similar to that of the CD25þCD127low/
population. Importantly, both studies identified functionally
suppressive CD127low/ human Treg populations indepen-
dent of their CD25 expression (Liu et al., 2006; Seddiki et al.,
2006a). Despite the presence of FoxP3þ cells, this had not
been demonstrated previously, owing to a contamination of
the CD25 and CD25low/intermediate populations with non-
Tregs. Therefore, it also raises the questions of whether all
FoxP3þ cells are necessarily Tregs and whether their activity
depends on the level of FoxP3 expression. Moreover, it has
been discussed that activated T cells transiently upregulate
FoxP3. Cells found in the CD127low population are suppres-
sive, regardless of their level of CD25 staining, and it might
be surprising that CD25þCD127low/ cells are robustly
suppressive, despite a lower expression of FoxP3. In this
study, however, we demonstrated that there was a large
percentage of CD127low/ cells that were not FoxP3þ .
Conversely, there was a large percentage of CD127þ cells
that did express FoxP3, suggesting that staining for FoxP3 and
CD127 did not represent the same Treg population. Interest-
ingly, the numbers of Treg cells stained by either antibody
were similar, and the different populations could be seen
only by multicolor flow cytometry. Thus, the isolation of pure
Treg populations for in vitro studies using either FoxP3 or
CD127 is not comparable, thus explaining the various results
by different groups in clinical studies. These results raise
critical issues because of important implications in determin-
ing quantitative differences in patients with a variety of
diseases.
Several groups have investigated the number and function
of Tregs in patients with autoimmune diseases. In some
settings, such as type 1 diabetes, autoimmune polyglandular
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Figure 5. Correlation between CD4þCD25þFoxP3þ cells and
CD4þCD25þCD127low/ cells in patients with systemic sclerosis (SSc).
To define the frequency of circulating CD4þCD25þFoxP3þ cells and
CD4þCD25þCD127low/ cells in SSc, peripheral blood mononuclear cells
(PBMCs) from patients with the disease were purified from peripheral blood
samples and stained for CD4, CD25, FoxP3, and CD127. PBMCs were gated
for CD4þ T cells (data not shown; see Figure 1a), and the percentage of
CD4þCD25þFoxP3þ cells among the CD4þ T cells (a, P5) and that of
CD4þCD25þCD127low/ cells among the CD4þ T cells (b, P6) were
determined. Moreover, the correlation between CD4þCD25þFoxP3þ cells
and CD4þCD25þCD127low/ cells was evaluated in patients with SSc (c)
using the same strategy as explained in Figure 6. As indicated in the circle
diagrams, 35.5% of the CD4þCD25þFoxP3þ cells could not be detected by
the CD4þCD25þCD127low/ strategy. Conversely, 40.7% of the
CD4þCD25þCD127low/ cells could not be detected by the
CD4þCD25þFoxP3þ strategy.
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Figure 6. Numbers of Tregs in normal healthy donors (NHDs) and
systemic sclerosis (SSc) patients using the CD4þCD25þFoxP3þ or
CD4þCD25þCD127low/ strategy. To investigate quantitative differences in
Treg populations in NHDs versus patients with SSc, peripheral blood
mononuclear cells (PBMCs) from both groups were stained for CD4, CD25,
FoxP3, and CD127. Statistical analysis revealed no significant difference
regarding the frequency of CD4þCD25þFoxP3þ Tregs among the CD4þ
cells between NHDs and patients with SSc. There was also no significant
difference in the percentage of CD4þCD25þCD127low/ cells between
NHDs and SSc patients. In addition, no significant difference could be found
between CD4þCD25þFoxP3þ cells and CD4þCD25þCD127low/ cells in
NHDs and SSc patients.
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syndrome type 1, and multiple sclerosis, the data found in the
literature regarding the number and function of
CD4þCD25high T cells suggest that diseased individuals
have either fewer or less functional Tregs (Kukreja et al.,
2002; Kriegel et al., 2004; Viglietta et al., 2004; Cox et al.,
2005). However, there have been controversial results in the
literature (De Kleer et al., 2004; Kuhn et al., 2009). It has
been suggested that this discrepancy might be the result of
differences in flow cytometry–based techniques for cell
separation or due to the different antibodies used. In this
study, we determined Treg numbers in patients with SSc, a
heterogeneous autoimmune disease with large variability in
the extent of cutaneous and systemic organ involvement,
analyzing the frequency of CD4þCD25þFoxP3þ T cells in
comparison with CD4þCD25þCD127low/– T cells. The data
showed only a slight difference in Treg numbers depending
on the expression of the cell-surface or intracellular marker.
Peripheral blood of patients with SSc, however, revealed that
only 64.5% of CD4þCD25þFoxP3þ cells were detected
within the CD4þCD25þCD127low/ population. Conver-
sely, 59.3% of CD4þCD25þCD127low/ cells were detected
within the CD4þCD25þFoxP3þ population. Finally, it is
interesting to note that some of the SSc patients had more
Tregs than the NHDs did. This is consistent with some studies
in other autoimmune diseases in which the frequency of
CD4þCD25high T cells was reported to be higher compared
with controls (Azab et al., 2008; Yan et al., 2008). We
hypothesize that rather than a Treg deficiency being the
cause of SSc disease precipitation, there is actually increased
Treg activity in an attempt to stem the increasingly aggressive
effector cells that may indeed become resistant to Tregs. This
must be confirmed in a larger number of patients and
correlated with clinical manifestations and therapeutic
strategies.
In summary, Tregs may contribute to the pathogenesis of
autoimmune diseases, cancer, and chronic infectious dis-
eases. Surface markers are needed to allow consistent
identification and functional testing of these cells. Given
the close association of Tregs with activated T cells, the
identification of Tregs in disease states is particularly
problematic. We have determined that the use of CD127
and FoxP3 as markers results in different populations of Tregs
being found in human peripheral blood, suggesting that
peripheral CD4þCD25þ Tregs cannot be accurately identi-
fied and purified using surface expression of CD127 as an
alternative to the transcription factor FoxP3. Thus, it will be
difficult to compare results directly, in terms of both Treg
numbers and functionality, by studying human clinical
samples, particularly in inflammatory conditions in which
there are significant numbers of activated effector T cells.
Therefore, more specific markers are needed for the selection
and expansion of T cells for diagnostics and therapeutic
applications in a flow cytometry–based strategy.
MATERIALS AND METHODS
Human blood and cell samples
Peripheral blood was obtained from 20 NHDs (16 men and 4
women, mean±SD age, 43.4±15.5 years) and from 12 patients
with SSc (six men and six women; mean±SD age, 54.0±8.7 years).
The diagnosis of SSc was based on the preliminary classification by
the American Rheumatism Association Subcommittee for Sclero-
derma Criteria (Subcommittee for Scleroderma Criteria of the
American Rheumatism Association Diagnostic and Therapeutic
Criteria Committee, 1980). All patients gave their informed consent
to participate in the study. The study was approved by the ethics
committee of the University of Heidelberg, Heidelberg, Germany,
and it was conducted according to the ethical guidelines at our
institution and the Declaration of Helsinki Principles.
Antibodies
Human mAbs (FITC-conjugated anti-CD4 and phycoerythrin-con-
jugated-anti-CD127) were obtained from BD Pharmingen (Heidel-
berg, Germany), and the APC-Cy7-conjugated anti-CD25 antibody
was purchased from Miltenyi Biotech (Bergisch Gladbach, Ger-
many). The APC-conjugated anti-FoxP3 antibody (clone PCH 101)
was obtained from eBioscience (San Diego, CA), and an isotype
control IgG-APC from BD Pharmingen was used.
Flow cytometry
PBMCs from NHDs and patients with SSc were purified by Ficoll
gradient centrifugation as previously described (Franz et al., 2007).
PBMCs were stained with surface mAbs against CD4, CD25, and
CD127, followed by FoxP3 intracellular staining if applicable. The
intracellular staining method to visualize FoxP3þ Tregs by flow
cytometry was performed according to the manufacturer’s protocol
and modified as follows. Cells (2.5 106) were stained with cell-
surface markers for 30minutes at 4 1C and fixed for 30minutes using
1 Fix/Perm buffer. After three washes, cells were permeabilized in
Perm buffer (eBioscience) for 30minutes, followed by three washes.
Cells were then blocked with normal rat serum and stained with anti-
human APC-conjugated FoxP3 antibody (clone PCH 101). Subse-
quently, cells were analyzed using a FACS Canto cytometer and
FACS-Diva software (BD Biosciences, San Jose, CA).
Statistical analysis
FACS analysis of peripheral circulating Tregs with regard to pie
charts of CD127 and FoxP3, as well as permeabilized and
nonpermeabilized T-cell data, is presented as means. To compare
these data, paired Student’s t-test was used. In scatter plots, Treg
numbers are presented as single values and median to compare
NHDs with patients with SSc using the Mann–Whitney U-test. Tests
were considered significant when Po0.05.
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